News
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
News
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
News
Beta-thalassemia gene therapy achieves lasting transfusion independence
“Seeing the restoration of iron metabolism, it really takes us a step closer to really thinking the term ‘cure’ might truly apply.”
News
Response endures in cemiplimab-treated patients with cutaneous SCC
MILAN – Time to response was “quite rapid” at a median of 1.9 months in both groups.
News
E-cigarettes beat nicotine patch for smoking cessation
The findings contrast with those of earlier studies, which showed a lesser effect of e-cigarettes as a stop-smoking strategy.